Contingent Value Rights Explained

Table of Contents

    Contingent value rights can help an acquisition close when buyer and seller disagree about an uncertain asset. The buyer pays part of the price at closing and promises additional consideration if defined future conditions are satisfied. For the shareholder, the challenge is deciding what that conditional promise is worth today.

    Start with the agreement: what triggers payment, by when, who controls the relevant business decisions, and how can holders enforce their rights? Then value the conditional cash flows separately from the closing proceeds. This guide uses U.S. transaction examples and explicitly hypothetical valuation assumptions; individual agreements and their governing law control.

    What Are Contingent Value Rights?

    A contingent value right (CVR) is a contractual entitlement to additional consideration under specified conditions. It can be issued to eligible target shareholders as part of an acquisition. A pharmaceutical CVR might depend on a defined regulatory or development milestone; a price-protection CVR might compensate for a specified shortfall in the buyer’s stock value. Actual agreements illustrate both structures. [1] [4]

    Separate Three Different Amounts

    Distinguish the consideration paid at closing, the CVR’s maximum possible future payment, and the present value of its conditional payments. An announced “up to” price does not make the maximum CVR amount certain.

    For example, Blueprint Medicines’ July 2025 closing disclosure described $129 cash plus one nontransferable CVR per eligible common share. The CVR could pay up to another $6 under its milestone terms. The completed acquisition did not turn those possible payments into an unconditional $135 cash entitlement. [2]

    Before a merger closes, even its fixed closing consideration remains subject to completion. After closing cash has actually been paid, uncertainty about a remaining CVR is a separate exposure. The broader mergers and acquisitions valuation question concerns the business, synergies and purchase price; CVR analysis concerns a particular conditional claim.

    Milestone CVRs vs Price-Protection CVRs

    The payment condition determines the appropriate model. Transferability and settlement form are additional terms to check; neither follows automatically from the type of trigger.

    Two CVR structures expose holders to different uncertainties
    Feature Milestone CVR Price-protection CVR
    Payment trigger A defined event, such as a specified approval or development milestone. A defined stock-price measure falls below a contractual threshold.
    Payment pattern May be one payment requiring all conditions, or separate payments for separate milestones. May increase with a price shortfall, subject to a cap and other adjustments.
    Key valuation inputs Joint event probabilities, deadlines, payment dates and the ability to collect. The exact payoff, price process, averaging window, maturity and settlement terms.
    Common modeling error Adding every maximum payment or treating related milestones as independent. Replacing a contract’s average price or extension option with a simple spot-price put.

    The BMS–Celgene agreement required all three specified milestones for one payment. Blueprint’s agreement instead defined two milestone payments with different deadlines. Their structures should not be interchanged merely because both involved pharmaceutical development. [1] [3]

    A historical price-protection example

    Viacom’s 1994 Paramount agreement provided a useful contrast. At the initial maturity, its CVR paid the positive excess of a $48 target over the greater of a defined market value and a $36 minimum. The initial maximum was therefore $48 − $36 = $12 per CVR. Market value used a specified median of trading-day averages rather than one closing quote. Viacom also had extension options that changed dates and thresholds, and could settle in cash or equivalent value of registered securities. [4]

    A separate M&A collar and exchange-ratio provision can adjust the stock delivered under an acquisition. A CVR can instead remain as a conditional right after closing. Similar price-protection purposes do not make their timing, instruments or enforcement identical.

    How to Read a CVR Agreement

    Use the executed CVR agreement alongside the merger documents, amendments and subsequent disclosures. A press release’s headline is a starting point, not the complete payment rule. Build a short term sheet before assigning probabilities:

    1. Identify the entitlement and obligor. Who receives how many rights, and which legal entity owes the payment? Check whether a parent guarantee, collateral or payment subordination exists.
    2. Write the exact trigger. For an approval milestone, identify the regulator, product, indication and required type of approval. For a sales milestone, identify the measurement and accounting definitions.
    3. Separate deadlines from payment dates. A milestone can have an achievement deadline followed by notice, calculation and payment periods. A successful event does not necessarily produce same-day cash.
    4. Map payment dependencies. Does one missed condition eliminate the entire payment, only its own tranche, or a later tranche as well?
    5. Identify control and information rights. Read development-efforts covenants, reporting and inspection provisions, and what happens if the product or business is sold.
    6. Read settlement and transfer terms. Cash versus securities, permitted transfers, the holder register, record dates and broker payment procedures can change the practical result.
    7. Read enforcement and amendment provisions. Identify who may act, participation thresholds, notice and cure requirements, costs, consent protections and which obligations survive termination.

    These are questions to resolve from the specific documents. Do not assume every CVR has the same efforts standard, trustee, holder threshold or protection against changes.

    Valuing a Milestone CVR

    For fixed payment dates, a simple scenario valuation weights each payment by the probability that all conditions for that payment are met, then discounts to the valuation date:

    Illustrative Probability-Weighted Present Value
    VCVR = Σj [pj × Xj / (1 + d)tj]
    For each conditional payment j: probability p, payment X, receipt time t in years, and a consistently chosen annual effective discount rate d.

    This simplified expression assumes full collection when a payment is triggered. If default, partial recovery or litigation delay matters, model those outcomes and dates too. The discount rate must match the probability and cash-flow framework. A scenario calculation using assumed real-world probabilities and an arbitrary rate is not automatically a market-consistent fair value.

    The familiar discounted cash flow principle still applies: timing affects value. But a whole-company discount rate from a business valuation is not automatically appropriate for a CVR’s specific event, credit and contractual risks.

    Use conditional probabilities for dependent milestones

    If payment requires both event A and event B, use their joint probability. In general:

    Joint Probability
    P(A and B) = P(A) × P(B given A)
    Multiplying two unconditional probabilities requires an independence assumption. The conditional formulation does not.

    Development, approval and commercialization can share scientific, manufacturing and managerial risks. A later commercial milestone may also be contractually payable only after an earlier milestone succeeds on time. Define that dependency before doing arithmetic.

    Worked Example: Two Conditional Pharma Payments

    Consider a fictional Harbor acquisition of Cedar Bio, valued immediately after closing. One eligible share has received $40 cash and one CVR. This invented contract promises:

    • $6 at the end of year 2 if condition A, a defined regulatory approval, is achieved by then.
    • An additional $4 at the end of year 3 if condition B, a defined commercial milestone, is achieved by then and A was achieved on time.

    Assume P(A) = 60% and P(B given A) = 50%. These are teaching assumptions, not observed or market-implied probabilities for an actual drug. Assume an 8% annual effective discount rate, full on-time collection, and no taxes, fees, litigation recovery or separate credit haircut. The simplified contract places payment exactly at the stated year-ends.

    Hypothetical mutually exclusive CVR outcomes
    Outcome Probability Year-2 cash Year-3 cash
    A and B achieved on time 60% × 50% = 30% $6 $4
    A achieved; B missed 60% × 50% = 30% $6 $0
    A missed 40% $0 $0

    The first payment occurs in both successful-A rows, so its probability is 60%. The second requires joint success, giving 60% × 50% = 30%. A missed A cannot be rescued by a later commercial event under this particular hypothetical contract.

    Value Each Receipt Separately

    Expected year-2 payment = 0.60 × $6 = $3.60.

    Expected year-3 payment = 0.30 × $4 = $1.20.

    CVR present value = $3.60 / 1.082 + $1.20 / 1.083 = $3.0864 + $0.9526 = $4.04, rounded after calculation.

    Modeled package value at closing = $40 + $4.0390 = $44.04.

    The maximum nominal receipts are $40 + $6 + $4 = $50, partly conditional and paid later. The $44.04 model result preserves the $40 already received while valuing the uncertain remainder under the stated assumptions.

    Check probability and timing sensitivity

    Keep all other assumptions fixed. If P(A) falls to 40% while P(B given A) stays 50%, joint success becomes 20%. CVR value falls to 0.40 × $6 / 1.082 + 0.20 × $4 / 1.083 = $2.69.

    Alternatively, retain the original probabilities but delay each payment by one year. Value becomes $3.60 / 1.083 + $1.20 / 1.084 = $3.74. This isolates a payment delay. Extending a milestone’s achievement deadline could also change its probability, requiring a separate scenario.

    When Option-Based Valuation Fits

    Now switch to a separate hypothetical price-protection CVR. It pays cash exactly one year from today, equal to the shortfall of one terminal stock price ST below $50, capped at $10. There is no averaging or extension option and no additional milestone.

    Capped Price-Protection Payoff
    Payoff = min[$10, max($50 − ST, 0)]
    Zero at or above $50; rising as the stock falls between $50 and $40; capped at $10 at or below $40.
    Hypothetical CVR payment at the one-year settlement date
    Terminal stock price (USD) CVR payment (USD per right)
    30 10
    40 10
    45 5
    50 0
    60 0

    The cap matters: a further decline below $40 does not increase this right’s payment. Algebraically, the payoff equals max($50 − ST, 0) − max($40 − ST, 0). That is the terminal payoff of a long $50-strike put option and a short $40-strike put with matching maturity and settlement.

    For an option-pricing illustration, assume the traded underlying is $50 today and can be only $60 or $40 in one year. Assume a 5% risk-free rate, no dividends, frictionless trading and borrowing, and full payment. The binomial option-pricing model uses a risk-neutral up weight:

    A Pricing Weight Is Different From a Forecast

    q = ($50 × 1.05 − $40) / ($60 − $40) = 0.625.

    The CVR pays $0 in the up state and $10 in the down state. Its model value is [0.625 × $0 + 0.375 × $10] / 1.05 = $3.57.

    The 62.5% weight comes from the artificial no-arbitrage pricing model, not an estimated real-world chance that the stock rises. Replication with a traded underlying and risk-free lending or borrowing explains this approach. A regulatory milestone generally cannot be replicated by trading the drug-development outcome, so a stock-option model cannot simply supply its success probability. [5]

    Actual price protection may require models of averaging, issuer extensions, changing thresholds, dividends and issuer credit. Viacom’s historical terms were more complex than this terminal-price illustration. Matching an option payoff also does not mean the CVR is a collateralized listed option.

    Buyer Control, Enforcement and Litigation Risk

    The buyer may control resources, development sequencing or commercial decisions after acquisition. Evaluate the covenant that constrains those choices and the information available to holders. A requirement to use defined diligent efforts does not guarantee that a regulator will approve a product.

    In the original BMS agreement, diligence, records, product-transfer provisions and trustee remedies sat alongside the payoff. Amendments had differentiated consent rules; certain adverse payment changes required each affected holder’s consent. Holder enforcement also had procedural conditions and a separate exception for due-payment suits. These provisions require reading together. [3]

    BMS–Celgene: expiry and litigation are separate questions

    The November 20, 2019 BMS agreement promised $9 per CVR only if all three defined milestones were met: liso-cel and ozanimod by December 31, 2020, and BB2121 by March 31, 2021. BMS reported in January 2021 that liso-cel missed its deadline, the agreement automatically terminated, and ordinary payment eligibility and NYSE trading ended. The agreement nevertheless preserved liability for certain prior material breaches. [3] [6]

    Litigation followed over alleged failures to use diligent efforts. On August 13, 2026, the Second Circuit vacated a dismissal and allowed UMB to maintain the trustee action, addressing standing, capacity and acceptance of its appointment. That procedural decision did not establish a breach or award CVR damages. [7]

    BMS’s October 29, 2026 quarterly disclosure continued to dispute the allegations and described the consolidated contract litigation as proceeding toward a scheduled January 2028 trial. That is the issuer’s dated account, not a final legal outcome or assurance that the schedule will hold. A potential litigation recovery has its own probability, costs and timing; it is not the original milestone payment becoming certain. [8]

    CVRs, Trading and Earnouts

    CVR is not a promise of a liquid market. Some rights are issued as transferable securities; others are restricted contractual entitlements. The BMS instrument had transfer and exchange-listing provisions. Blueprint’s executed agreement prohibited ordinary sales and listing, with limited permitted transfers such as specified inheritance and nominee transfers. Book-entry registration records an entitlement; it does not establish tradability. [1] [3]

    CVR

    • Specifies a conditional payment right that can be distributed to target holders.
    • May have transferable-security or restricted contractual terms.
    • Requires analysis of its own trigger, payment and enforcement provisions.

    Earnout

    • Describes contingent acquisition consideration linked to future outcomes.
    • Can be documented directly in a purchase agreement.
    • The label alone does not create a separately tradeable instrument.

    The economic purposes can overlap. Read the actual instrument rather than relying on a naming distinction to decide whether securities rules apply, whether a sale is permitted or how proceeds are taxed.

    For a transferable CVR, check executable quotes, volume, spreads, brokerage support and settlement arrangements. A quote is not proof that a large position can be sold at that price. For a restricted right, plan around the permitted-transfer and payment-register procedures instead of assuming an exchange exit.

    Merger arbitrage analyzes the risk of collecting announced consideration before closing. A CVR can leave an investor exposed to a milestone long after the ordinary cash or stock transaction finishes. Any quoted CVR price reflects more than one unknown; without assumptions about timing, risk, recovery and terms, it does not reveal an actual success probability.

    Common Mistakes

    • Adding the maximum CVR to closing cash at full value. Separate uncertain later proceeds and discount them under explicit assumptions.
    • Multiplying unconditional milestone probabilities automatically. Use joint probabilities or a conditional tree that captures dependencies.
    • Confusing approval with timely contractual approval. A successful product can still miss the defined indication or deadline.
    • Discounting from the event date instead of receipt. Include the agreement’s notice, calculation and settlement timetable.
    • Double-counting risk adjustments. Keep probability, recovery and discount-rate assumptions consistent rather than repeatedly penalizing the same loss.
    • Assuming a trustee guarantees recovery. Authority, notices, participation and funding requirements affect practical enforcement.
    • Treating expiry as a complete legal-outcome summary. Read survival terms and later proceedings before asserting that every claim is extinguished.

    Limitations of CVR Valuation

    Contract Precision Does Not Create Forecast Certainty

    An exact payment formula can coexist with uncertain science, business decisions, credit, legal interpretation and collection timing. A precise model result is only as useful as its assumptions.

    Scenario analysis can expose the consequences of different assumptions, but it does not establish the correct success probabilities. An option model requires defensible underlying dynamics and a suitable pricing framework. Neither method replaces reading the documents or assessing the issuer’s ability to pay.

    The examples exclude taxes and transaction costs. Tax character, basis allocation, withholding and reporting can depend on the instrument and holder’s circumstances; consult the transaction’s tax disclosures and qualified advisers. A contractual description alone does not resolve every legal or tax classification.

    Frequently Asked Questions

    Yes. If no payment condition is met within its required period, the ordinary contractual payout can be zero. Whether a separate breach claim survives depends on the agreement and applicable law. Missing a milestone and proving that the buyer violated an obligation are different questions.

    Only if the specific instrument and applicable rules permit it. Some CVRs have transfer and listing arrangements; others prohibit ordinary sales while permitting narrow transfers such as inheritance. Even a transferable right may have little trading liquidity. Confirm the actual right and your broker’s procedures.

    That can be a starting expected cash amount for one all-or-nothing payment, if the probability covers every required condition. It is not yet present value. Separate payment tranches can have different probabilities and receipt dates; default, partial recovery and costs may require additional scenarios.

    No. A stock-price CVR may have an option-like payoff, but averaging, caps, extension rights and issuer credit can require a different model. A clinical or regulatory milestone is not automatically a tradeable underlying that can be replicated using stock and cash. Choose the model from the contract and risks.

    A conditional payment entitlement by itself should not be treated as common-stock ownership or a claim on every future business profit. Read the instrument’s voting, distribution and settlement provisions. Any acquirer shares delivered separately at closing, or securities later used for settlement, have their own rights.

    Sources

    1. Aventis and Continental Stock Transfer & Trust: executed CVR agreement, July 15, 2025. Definitions, milestone periods and payments; Sections 2.1–2.3 on contractual rights, transfer restrictions and registration.
    2. Blueprint Medicines: Form 8-K signed July 18, 2025. July 17 closing, cash consideration and conditional CVR entitlement.
    3. Bristol-Myers Squibb and Equiniti: executed Series B CVR agreement, November 20, 2019. Definitions, termination/survival, payment, amendments, covenants and remedies.
    4. Viacom–Paramount: February 4, 1994 amended merger agreement, Annex C. Historical principal terms of price-protection CVRs, averaging, extensions and settlement.
    5. Aswath Damodaran, NYU Stern: The Promise and Peril of Real Options, undated author-hosted paper. Put payoffs, binomial replication and limitations for untraded underlying assets.
    6. Bristol-Myers Squibb: January 4, 2021 Form 8-K, Item 8.01. Company’s January 1 milestone/termination announcement.
    7. Second Circuit: UMB Bank v. Bristol-Myers, August 13, 2026. Trustee capacity, vacatur and remand; no merits damages award.
    8. Bristol-Myers Squibb: September 30, 2026 Form 10-Q, signed October 29, 2026. Note 18, Contingent Value Rights Litigations; issuer’s dated litigation-status disclosure.

    Sources accessed November 15, 2026. Harbor–Cedar probabilities, rates, cash flows and the separate option example are hypothetical calculations, not observed CVR prices or investment recommendations.

    Disclaimer

    This article is for educational and informational purposes only and does not constitute investment, legal, medical or tax advice. CVR rights and outcomes depend on the operative documents, amendments, applicable law and facts. Examples are not recommendations to buy, sell or hedge a security. Consult qualified professionals about an actual transaction or holding.